The preclinical experiments demonstrated trametinib had broad anticancer activity in multiple cancer models by inducing cell cycle arrest, apoptosis and growth inhibition in vitro and in vivo, especially in cancer cells with activating mutations of BRAF and KRAS in the MAPK pathway [14]. The gene discussed is KRAS; the disease is cancer.